Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 9, 2005, Pages 5058-5063

  Dhindsa, Sandeep ^a   Tripathy, Devjit ^a   Sanalkumar, Nishanth ^a   Ravishankar, Shreyas ^a   Ghanim, Husam ^a   Aljada, Ahmad ^a   Dandona, Paresh ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Diabetes Endocrinology Center of Western New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AUTACOID; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; HEPARIN; INSULIN; INSULIN SENSITIZING AGENT; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; HYPERINSULINEMIA; INFUSION; INSULIN RESISTANCE; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; C-REACTIVE PROTEIN; DRUG COMBINATIONS; EMULSIONS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEPARIN; HUMANS; INFUSION PUMPS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; SERUM AMYLOID A PROTEIN; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 24344456645     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0223     Document Type: Article

References (50)

1. Reaven GM 1995 The fourth musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 38:3-13
2. Randle PJ, Garland PB, Hales CN, NewsholmeEA 1963 The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
3. Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X, Coleman E, Smith C 1991 Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88:960-966
4. Boden G, Chen X 1995 Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 96:1261-1268
5. Shulman GI 2000 Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176
6. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI 1999 Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259
7. Itani SI, Ruderman NB, Schmieder F, Boden G 2002 Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51:2005-2011
8. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI 1999 Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes 48:1270-1274
9. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P 2003 Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52:2882-2887
10. Dandona P, Aljada A, BandyopadhyayA2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7
11. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
12. Bays H, Mandarino L, DeFronzo RA 2004 Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478
13. Hevener AL, Reichart D, Janez A, Olefsky J 2001 Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 50:2316-2322
14. Ye JM, Frangioudakis G, Iglesias MA, Furler SM, Ellis B, Dzamko N, Cooney GJ, Kraegen EW 2002 Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology 143:4527-4535
15. Chen XP, Yang WY, Bu S, Xiao JZ, Liu XL, Wang N, Zhao WH 2004 [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. Zhonghua Nei Ke Za Zhi 43:280-283
16. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, KraegenEW 1994 A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210
17. Srinivasan K, Patole PS, Kaul CL, Ramarao P 2004 Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 26:327-333
18. Khoursheed M, Miles PD, Gao KM, Lee MK, Moossa AR, Olefsky JM 1995 Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism 44:1489-1494
19. Kitakoshi K, Oshida Y, Nakai N, Han YQ, Sato Y 2001 Effects of troglitazone and voluntary running on insulin resistance-induced high fat diet in the rat. Horm Metab Res 33:365-369
20. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P 2001 Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 86:3250-3256
21. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P 2004 Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728-2735
22. Dandona P, Aljada A 2002 A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 90:27G-33G
23. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P 2001 Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306-1312
24. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
25. Tschritter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E, Teigeler A, Haring H, Fritsche A 2002 The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 51:2854-2860
26. Rassam AG, McLeod J, Burge MR, Schade DS 1998 Use of the HemoCue blood glucose analyzer in research studies. Diabetes Care 21:1369-1370
27. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino Jr CH 2000 Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124
28. Tosi MF, HamedaniA 1992Arapid, specific assay for superoxide release from phagocytes in small volumes of whole blood. Am J Clin Pathol 97:566-573
29. Hancock JT, Jones OT 1987 The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 242:103-107
30. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F 2005 The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95
31. Racette SB, Davis AO, McGill JB, Klein S 2002 Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism 51:169-174
32. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF 2002 The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
33. Arner P 2003 The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137-145
34. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y 1999 The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35-41
35. Aljada A, Ghanim H, Friedman J, Garg R, Mohanty P, Dandona P 2001 Troglitazone reduces the expression of PPARγ while stimulating that of PPARα in mononuclear cells in obese subjects. J Clin Endocrinol Metab 86:3130-3133
36. Frayn KN 2002 Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201-1210
37. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR 2003 Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285:E354-E362
38. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhausl W, Shulman GI 2000 Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49:701-707
39. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, Jensen MD, Rizza RA 2002 Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 51:301-310
40. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA 2003 Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370
41. Frias JP, Yu JG, Kruszynska YT, Olefsky JM 2000 Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23:64-69
42. Levin K, Hother-Nielsen O, Henriksen JE, Beck-Nielsen H 2004 Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes. Diabetes Care 27:148-154
43. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M 2004 Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629
44. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, Nuutila P 2003 Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290
45. Hotamisligil GS 2003 Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27(Suppl 3):S53-S55
46. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE 2001 Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677
47. Garg R, Tripathy D, Dandona P 2003 Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 4:487-492
48. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI 2002 Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684
49. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S 2001 Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265
50. Dandona P, Aljada A, Mohanty P 2002 The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924-930